All articles tagged with #atopic dermatitis
Johnson & Johnson has discontinued its mid-stage trial of the experimental eczema drug JNJ-5939 after it failed to meet efficacy goals, but remains committed to developing other treatments for atopic dermatitis.
Johnson & Johnson announced that their Phase 2b DUPLEX-AD study for JNJ-5939 in treating moderate to severe atopic dermatitis was terminated early after not meeting efficacy criteria, though the drug was well tolerated. The company remains committed to developing new treatments for the high-need condition.
Sanofi's anti-OX40L antibody, amlitelimab, has successfully met the primary endpoint in a Phase IIb trial for atopic dermatitis, showing up to a 61.5% improvement in eczema severity. The detailed data from the trial has paved the way for a Phase III study in the first half of next year, strengthening Sanofi's immunology portfolio. Amlitelimab was acquired by Sanofi through its acquisition of Kymab in 2021.